•
Sep 30, 2023

Prelude Therapeutics Q3 2023 Earnings Report

EPS
-$0.45
Previous year: -$0.63
-28.6%
Gross Profit
-$279K
Cash and Equivalents
$231M
Previous year: $52M
+343.1%
Free Cash Flow
-$26.3M
Previous year: -$21.4M
+23.0%
Total Assets
$259M
Previous year: $242M
+6.7%

Prelude Therapeutics

Prelude Therapeutics